Genetic Medicine’s Bottleneck Has Shifted From Discovery to Delivery

Jake Becraft describes Strand Therapeutics as a company designing “next generation genetic medicines,” but the phrase only becomes useful once he reduces the biology to its operating problem. Cells contain DNA. DNA makes RNA copies. RNA makes proteins. Proteins, in his framing, are “what we think of as our being”: skin, hair, organs, and the working machinery of cells.

Disease, in that account, often comes down to proteins being absent, malformed, misplaced, or otherwise made incorrectly. Becraft’s claim is not that medicine lacks knowledge about which proteins matter. In many cases, he says, decades of work have identified what has gone wrong and what would need to go right. The missing capability is commanding the right cells, in the right places, to make the right proteins safely and effectively.

That is the premise behind Strand’s use of RNA. RNA is the message. COVID vaccines made many people familiar with mRNA, but Becraft argues those vaccines are “very small examples of what RNA could actually be utilized to do.” Strand’s ambition is to send RNA messages into diseased areas of the body so cells can be pushed back toward homeostasis, corrected, or, in cancer, destroyed.

Strand’s own homepage, shown during the discussion, describes the company as a clinical-stage biotechnology company with “a pipeline of breakthrough mRNA therapeutics for cancers and autoimmune diseases.” It frames the company around three mRNA challenges: targeting, safety, and potency. Becraft later turns those three into the real structure hidden beneath the biotech cliché that “the issue is delivery.” Delivery, he says, is not wrong as a diagnosis; it is incomplete. What the industry calls delivery is, in his words, “three children in their father’s trench coat pretending to be an adult”: potency, specificity, and delivery.

That distinction matters because Becraft believes genetic medicine has spent roughly 30 years proving it can work in the liver while leaving the harder question unresolved. The liver naturally filters blood, so genetic medicines delivered through the bloodstream tend to accumulate there. In his shorthand, the field’s joke has been: step one, prove it works in the liver; step two, question mark; step three, treat all these diseases. After decades, he says, step one has been nailed. Step two remains the problem.

Strand’s long-term goal, as he presents it, is to solve step two: intravenous delivery of genetic medicines to tissues beyond the liver. The nearer-term manifestation is cancer. But the broader claim is infrastructure. If medicine can learn to deliver genetic instructions to specific cell types and organs, then new discoveries from protein engineering, gene editing, AI-based design, and disease sequencing will have a way to become usable therapies rather than laboratory artifacts.

Becraft is careful to distinguish research ambition from commercial medical reality. Strand, he says, is not trying to join the ranks of scientists who have “cured mice of cancer.” Its goal is to cure “human beings of human being cancer” and human diseases in a way that is safe, effective, scalable, and minimally disruptive to patients’ lives.

The image that first caught Tim Ferriss’s attention was not an abstraction about programmable medicine. It was a patient scan.

Becraft says the patient was among the first enrolled in Strand’s early oncology trial: a stage four melanoma patient who had exhausted available options. In early-stage oncology trials, he explains, patients often arrive after standard therapies and second-line therapies have failed. This patient had aggressive cutaneous metastases across the skin and visceral metastases in organs and other areas, including the lungs, muscle deposits, and bone deposits.

The PET scan comparison was stark: at Week 12, the body silhouette was dotted with metastatic lesions; at Week 30, those lesions were dramatically reduced or absent. Becraft says Strand presented the image at ASCO, the American Society of Clinical Oncology meeting, in a poster titled, “Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients with advanced solid tumors.” A close-up of the poster identified the patient as a 72-year-old female with melanoma, treated at 30 micrograms, with a RECIST partial response and complete metabolic response by PET.

Becraft presents the image as both clinical evidence and personal evidence: “a body riddled with cancers” and then “no more.” He says that more than a year and a half later, the patient still had no detectable lesions.

For him, the patient also marks a different kind of achievement. Strand is only part of what he describes as a broader career mission to make genetic medicine work correctly for patients. If the work had helped only one person, he says, that alone would have made the career meaningful. Strand’s ambitions are much larger, but the first clear human response was the first time he felt the science had gone into the world and helped “someone’s grandmother.”

The treatment’s mechanism begins with Becraft’s distinction between chemotherapy and immunotherapy. He says people are fairly familiar with chemotherapy; immunotherapy is the ability to activate the immune system to attack cancer directly. Becraft points to checkpoint inhibitor drugs such as Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo as major commercial and medical successes. These drugs work, in broad terms, by interfering with cancer’s ability to use “I’m you” signals that prevent the immune system from attacking the body’s own cells.

The problem, as Becraft describes it, is mechanistic similarity. If Keytruda does not work for a patient, the odds that similar next therapies will work begin to drop. He allows that oncologists would add nuance by cancer type, combination, and subtype, but his broad point is that current checkpoint approaches do not provide enough distinct ways to excite the immune system.

An older immunology idea, going back to the 1990s in his telling, is more direct: instead of only blocking cancer’s ability to hide, make the tumor broadcast an activation signal. The tumor should effectively scream, “I am a foreign object. Please come and eat me.” The concept has been hard to realize. Injecting the signal itself into tumors has tended either to dissipate too quickly, fail to generate enough efficacy, or activate the immune system in unwanted places and cause toxicity.

Strand’s approach, Becraft says, is to deliver instructions into cancer cells so the cancer itself makes and sends the signal. The signal is artificial in that the company made the message in a lab, but the drug is not simply dumping the signal into the body. It is “a message that tricks the cancer into sending the signal.” Becraft argues that this improves both safety and efficacy because it recapitulates a more natural immune mechanism: dysregulated cells should signal that something is wrong, and the immune system should clear them before they become tumors.

In the first drug, administration was direct. Strand’s medicine was injected into the tumor. The immune system came into the tumor and killed it. More importantly, Becraft says, the killing process educated the immune system about what the tumor looked like, enabling it to identify other tumors elsewhere in the body.

Ferriss presses the practical point: the patient’s visible lesions were cutaneous, but the response included visceral disease. Becraft names the phenomenon: the abscopal effect. One tumor receives the activating drug; the immune system then attacks other tumors. The effect itself is not new, but Becraft says prior observations were limited — for example, an injected lesion on the chest and another lesion on the shoulder shrinking in the same regional environment. The harder and more important question is whether an injected skin lesion can drive responses in deep organ metastases, such as lung or liver lesions, because those are what kill melanoma patients.

Becraft says Strand is, to his knowledge, one of the first companies, if not the first, to demonstrate this extent of abscopal response in visceral, deep organ metastases across multiple patients using a direct injectable drug. He emphasizes that the striking patient scan is not the entire case: “This isn’t a one-off.” Of the first three patients in the trial in summer 2024, he says, two were still on the trial 18 months later, which he calls “fairly shocking” for a Phase 1 study.

Yet he immediately separates a drug that works from a drug that can reach patients. A therapy can be a good drug if it helps a person in a way that is difficult to replicate. A good product must be deliverable to many patients through real healthcare systems. Injecting tumors directly can work, especially for skin cancer lesions and trained oncologists. But as a product, it has limits: rural communities may lack trained clinicians; skin lesions may already have been surgically removed; lung cancer and other internal tumors are harder to inject; and the method fits only some patient and tumor situations.

Becraft’s preferred product form is infusion. Cancer care already has infusion clinics. Patients come in, are hooked up to IV therapies, and oncologists and staff monitor multiple patients. If Strand wants the largest near-term medical impact, he argues, its drugs must plug into that infrastructure rather than requiring healthcare to reorganize itself around the company.

That is why intravenous genetic medicine matters. The bloodstream reaches the body. If drugs can travel through it and arrive at the intended tissue, the product expands from direct injection into something closer to standard oncology practice.

Ferriss repeatedly uses SpaceX as a communication analogy: a first-principles engineering platform that becomes payload-agnostic once the hard work of launch is solved. Jake Becraft accepts the analogy but narrows it. He is leaning away from words like “programmable” or “programming” when describing Strand because they can confuse people about what a platform is.

In his current framing, Strand is not a single platform for all genetic medicine. It is a flywheel of technologies, AI models, manufacturing expertise, talent, and trade secrets that allow the company to build platforms for areas of the body it wants to access. Tumor delivery is a platform. T-cell delivery is a platform. Future kidney or brain delivery would be other platforms.

This is where, in Becraft’s view, parts of the RNA field got lost. He says Moderna treated a platform too broadly — as though a tumor platform would also work for liver, kidney, and everything else. Becraft’s view is that this is not true. Injecting into tumors is different from IV delivery to tumors; that is different from getting to T cells; that is different from kidney; that is different from brain. Each is its own engineering problem and, if solved, its own platform.

Ferriss sharpens the analogy: getting satellites to orbit is different from getting to the Moon, which is different from getting to Mars. Becraft agrees. SpaceX did not begin with Starship. It began with smaller, more limited products, built knowledge, and expanded. In Becraft’s version, Strand’s first direct-injection oncology drug was the minimum viable product that mattered.

STX-003, a tumor-targeted mRNA therapy shown in a Strand animation as a “smart switch” that is off in healthy cells and on in cancer cells, is, in Becraft’s description, both a drug and a tumor platform. He says it was coming to the clinic six months ahead of schedule. The animation describes STX-003 as “a new kind of targeted mRNA therapy from Strand Therapeutics” that “acts like a smart switch” and activates only in tumors, with OFF in healthy cells and ON in cancer cells. Becraft uses that kind of example to frame Strand’s platform claim around tissue- and cell-specific behavior, not merely around putting RNA somewhere in the body.

The reason a platform matters, Becraft says, is not branding. Biotech companies have claimed platform status for 20 years because investors assign premiums to technologies that can become multiple drugs. But many such claims have been weak. A true therapeutic platform, in his definition, creates common technological infrastructure from which multiple medicines can be built. The next medicine should not start back at square one.

He uses Moderna’s COVID vaccine as an example of platform speed, while later acknowledging that the analogy can become politically charged. The popular story says Moderna designed a COVID vaccine in 62 days after identifying the relevant antigen sequence. Becraft says that is true but incomplete: Moderna had spent roughly 12 years building the underlying RNA sequences, particles, and vaccine knowledge that made a plug-and-play substitution possible. The speed came from prior infrastructure.

Ferriss offers a non-biotech analogy: if Uber Eats already has the systems to deliver hamburgers, and then it starts delivering vaccines, it did not build the whole delivery system in 60 days. It changed what moved through a preexisting system. Becraft accepts the point and divides the future of medicine into two buckets. One is new drug technology: programmable medicines, controllable genetic medicines, personalized or adaptable drug designs. The second is physical deployment infrastructure: small-scale manufacturing, clinical supply chains, and systems that can deliver advanced medicines nationally and globally.

Strand is developing the drug-technology side in the examples Becraft emphasizes: biological delivery platforms for tumors, T cells, and eventually other tissues. But he argues the physical deployment bucket will become just as important if medicine becomes more personalized. Without manufacturing and clinical deployment infrastructure, bespoke or narrow-indication drugs remain economically impractical.

The bottleneck is shifting. For decades, discovery was the constraint: identifying proteins, targets, mechanisms, and disease biology. AI systems such as AlphaFold, protein-design tools, sequencing, and computational disease classification are changing that. Becraft says the world is moving toward a state where it knows many more possible therapeutic interventions than it can deploy. In his SpaceX analogy, medicine will soon have a backlog of satellites and no scalable way to get them into orbit.

Jake Becraft’s largest managerial constraint is not only scientific. It is financial architecture. He says U.S. biotechnology is structurally incentivized to make minor steps forward, pursue single assets, and sell them before commercialization. Unlike technology markets, where founders routinely announce plans to build generational companies, biotech companies often work like real estate development: take an idea from point A to point B, produce evidence that it works, then sell the asset.

Tim Ferriss seizes on the analogy because it makes the current incentive structure memorable. Becraft’s point is that the traditional biotech financing model often resembles private equity asset development more than company building. The company learns from the process, but the technology may not compound. In classic drug development, a firm builds one molecule, runs the process, and, if it succeeds, gets it approved. The next drug often starts from the beginning. Scientific knowledge becomes public through papers, clinical results, and regulatory disclosures. The organization gains experience, but the platform does not necessarily reduce risk for future medicines.

That model conflicts with what Becraft says Strand is trying to do. He does not want to build a better widget and exit. He wants to change how medicines are built. That requires a long and expensive road, with constant reinvestment in the research engine. Even if Strand eventually has approved drugs and revenue, he says, the ambition is for research to keep consuming resources until the company breaks through to a much larger scale.

Becraft describes the CEO’s job in that context as finding globally aligned collaborators, capital partners, and institutions willing to support a 10-, 20-, or 30-year medicine-building thesis. Investors seeking the best return between now and next year may not be the right fit. Strand, he says, wants to be the long-term massive return while pushing medicine forward.

Ferriss points to SpaceX and Amazon as precedents for patient capital around long-horizon infrastructure. Becraft dwells on Amazon because it demonstrates how a founder can repeatedly explain a long-term vision in public markets. He recommends reading Jeff Bezos’s shareholder letters from Amazon’s first public year through the end of Bezos’s tenure as CEO, knowing how the company ultimately developed. His lesson is not that every bet pays off. It is that Amazon kept saying what it was doing, making long-term infrastructure bets, and bringing investors along before some of those bets became obvious.

Becraft applies that to Strand: the company needs to say publicly what it is doing. It needs to attract partners, remind current stakeholders of the mission, and make clear when short-term exit ramps appear whether they match the company’s true value. If a company is building well, he says, exit ramps will always come. The question is whether to take them. A clear mission helps decide.

He borrows an investing phrase to describe Strand’s desired moment: “post-conviction, pre-consensus.” Insiders and technologists may know a technology is working before the broader market agrees. In AI, he says, there was likely a period inside OpenAI before ChatGPT or DALL-E when internal conviction was high but public consensus had not formed. Once the public sees it, valuation changes. Strand wants to understand when it reaches that post-conviction moment and then build toward broader consensus.

The industry’s acquisition orientation is, in Becraft’s view, one reason biotech has lost ambition. As pharmaceutical companies consolidated and became larger, they struggled to do research internally and began buying smaller companies. Capital markets then built biotech companies for that buyer. The practical result is that innovators begin designing around what pharma might want to acquire.

Becraft says this dynamic has become so entrenched that public investors sometimes “short the launch” when a biotech company gets a drug approved and tries to commercialize it itself. The bet is that the company will mishandle launch because so few biotechs have retained that muscle. He does not call this nefarious. He calls it the market reacting to reality. But the reality is revealing: biotech has become, in his phrase, “a little brother to the pharmaceutical industry,” a pool of assets for larger buyers.

Ferriss compares the distortion to a tech ecosystem in which every startup is built only to satisfy the anticipated acquisition tastes of Meta, Google, or Netflix. Becraft agrees: if entrepreneurs build for a small group of buyers’ near-term preferences, ambition narrows.

Jake Becraft’s strongest policy claim is that the United States is losing biomedical competitiveness to China because the U.S. is slower and more expensive at the stage that matters most: first-in-human clinical trials. China, he says, has built an industrialized clinical-trial infrastructure that allows companies to test faster and cheaper. What began as a place for American companies to run trials, collect data, and bring it back to the FDA has become a flywheel for Chinese companies. They can run faster trials at home, develop Chinese-discovered drugs, and bring them to the United States. Capital notices efficiency and follows it.

Becraft’s proposed reform is direct: remove the FDA from direct permission-based oversight at the beginning of many first-in-human trials and shift toward a notification model resembling Australia’s Clinical Trial Notification system. His target is not final drug approval. He says the FDA should focus on approving drugs based on efficacy and safety. The proposed change concerns the first administration of a new medicine to humans, especially where institutional review boards can evaluate safety and trial suitability.

He explains the current U.S. process through the IND, or Investigational New Drug application. Before a first-in-human trial can begin in the United States, a company submits an IND to the FDA. Becraft says Strand’s first trial IND was 22,000 pages. Writing it requires professional writers, formal systems, extensive studies, manufacturing documentation, and analytics. He estimates the total cost can reach $25 million and take 18 months before a company can begin.

After FDA clearance, a company still goes to hospital Institutional Review Boards. Those IRBs already assess whether to run the trial, evaluate safety and efficacy data, and decide whether the trial is appropriate for their patients and institution. Becraft’s argument is that the U.S. has layered a costly national permission system in front of institutional decision-makers who must still make the safety decision.

In Australia, he says, many first-in-human trials proceed through a notification system. Regulators are notified; the company works with IRBs; some drug categories may still require formal approval, but the default is not the same pass/fail permission gate. Becraft wants a U.S. transition system in which certified IRBs — potentially centralized and professionalized across multiple hospitals — can approve early trials while notifying regulators.

He anticipates the safety objection. Patient safety, he says, is number one from every serious perspective. Nothing would kill a company faster or weigh more heavily on him personally than harming patients through sloppiness. Hospitals also have powerful incentives not to harm patients in their trials. His claim is not that oversight should disappear. It is that the workload should be distributed through IRBs and that the FDA should not be treated as “magical” in early safety oversight.

The current system, he argues, also distorts patient access and site selection. If a company spends $25 million and 18 months on an IND, its board will push it to run trials at top cancer centers such as MD Anderson or Sloan Kettering. That concentrates trials in already overburdened elite sites. It leaves many capable hospitals outside early trial networks. It also leaves Americans who have exhausted standard care without practical access to experimental therapies unless they can travel to major centers.

Ferriss asks how politically possible such reform is. Becraft says that, in the prior decade, he had not seen the FDA environment more open to a radical transformation — radical, he clarifies, by government bureaucracy standards. Bureaucracies tend to add oversight rather than give it up. He compares the accumulation of regulatory layers to the problem with nuclear energy in America: each new rule creates support industries around the machinery, and the system rarely steps back to ask why it is doing what it is doing.

Still, Becraft gives the reform a 50 percent likelihood within two years. He says he would not spend time discussing it with policymakers if he thought it were merely a complaint. He believes it is possible and existential: without it, the United States risks losing a large share of drug development to China.

He also sees global competition beyond China. Countries in Asia and the Middle East, including the UAE, are watching closely and could make aggressive bets to attract Western companies and biomedical innovation. Ferriss notes his own impression that Abu Dhabi and the UAE can move with striking speed in health policy. Becraft says Strand has spoken less with the UAE than with some other countries in the region, but he views allied countries with similar values as potential partners in building innovative solutions to major human problems.

After Jake Becraft and Tim Ferriss first worked through the policy story, Becraft’s op-ed ran in The Washington Post under the headline, “The U.S. can’t afford to offshore clinical trials to China,” with the subhead, “A burdensome regulatory environment is pushing clinical trials overseas.” The Washington Post page identified Becraft as the author and the piece as an opinion article. Becraft says the op-ed spread through biotech and medical policy circles. Some readers responded to the clinical-trial reform idea as new and compelling; others were surprised by the risk that the U.S. biomedical industrial base could move overseas, with China benefiting from U.S. regulatory friction.

The op-ed was followed by congressional interest. Becraft says that about a day after publication, a congressional staff member reached out about a hearing on risks to the biomedical industrial supply chain and U.S. biomedical industry related to China. That created an opportunity to refine the message for policymakers.

Ferriss and Becraft tested variations of the op-ed framing using PickFu, a tool Ferriss describes as human-plus-AI split testing for headlines, product images, campaigns, and similar decisions. Ferriss says the point was not necessarily to change the Washington Post headline, which was already published and subject to many stakeholders. The point was to learn which framing should be used in person, on stage, in testimony, and when sharing the article.

The lesson Becraft took from the response was that the most effective version had an opportunistic tone: this is the problem, but we can fix it. He says that should have been obvious, but it changed the way he presented the argument on Capitol Hill. A message that everything is burning leaves policymakers with little to do. A message that bad things are happening, the solution is in their power, and the country can act now gives them a role.

Ferriss generalizes the lesson to nonfiction and advocacy: a title that only says a problem is getting worse may repel readers; a title that promises the problem is not inevitable gives people a reason to engage. Becraft frames it more bluntly as a rule for scientists: no one will learn until they care. In scientific settings, he says, interest is often assumed. At MIT, he could talk about RNA medicine and people would ask for more because the science itself was intrinsically interesting to them. Investors, policymakers, and general audiences require motivation first.

Becraft says the reframed message helped in testimony and in meetings around Washington. He then points to what he describes as a rapid policy echo: in his account, the President’s legislative and budget priorities included the idea of removing barriers to getting early-stage experimental medicines to American patients through FDA reform. The on-screen material showed an Office of Federal Relations page about President Trump’s FY27 budget request, including broader budget context; Becraft supplies the claim that the relevant reform idea appeared in the President’s recommendations.

He is cautious that nothing is done. Legislative priorities must be codified; Congress must act; the FDA must adapt. But he calls the speed remarkable for Washington and says it should encourage more people to get involved. In less than two months, by his account, a message refined through an op-ed, testing, congressional testimony, and meetings had found a high-level policy echo.

For Becraft, the experience changed not only the policy campaign but Strand’s broader communication strategy. Bring the hook and solution up front. Explain the problem once people care. Then move into the nuance.

Jake Becraft’s longer draft, with the working title “RNA Medicine and the Rise of Platform Therapeutics,” attempts to explain where he thinks medicine is going over the next 10 to 15 years. The policy story sits on top of that future because biotech, like rockets, has long development timelines, high upfront costs, and binary outcomes: the drug works or it does not; the rocket reaches orbit or it blows up.

He repeatedly compares medicine to commercial space, but with a caveat. Putting a medicine into a human is not the same as launching a rocket that can explode over the Gulf of Mexico. Human safety changes the moral and regulatory calculus. But he argues that medicine still needs common-sense reform that enables faster experimentation and feedback if the platform future is to arrive.

The future he sketches is not simply larger drugs for larger markets. It is more refined disease categories, smaller indications, more variants of drugs, and eventually more personalized therapies. Policy and payment systems, he argues, are currently built around a different model: a drug for a large population, a negotiated or paid price, a period of brand-name sales, eventual generic competition, and incremental improvement. If medicine shifts toward many variants for smaller groups, regulation and payment must adapt.

Becraft warns of two failure modes. One is that only the ultra-rich receive disruptive individualized medicines because the system cannot commercialize and distribute them quickly enough. The other is that inability to pay or underwrite the ecosystem makes the investment thesis unattractive, cutting off laboratory innovations before they reach people.

He sees the historic precedent in the early biotechnology era. Ferriss and Becraft both cite Sally Smith Hughes’s book on Genentech, which Ferriss calls one of the best business books he has read because of its concrete treatment of contracts, negotiations, mistakes, luck, university errors, and survival. Becraft also points to Genzyme and Henri Termeer as examples of policy innovation around rare-disease medicines. A Congressional Research Service document shown during the discussion summarized the Orphan Drug Act, including its 1983 enactment and incentives such as tax credits, grants, and market exclusivity. A White House AI action-plan document was also shown; Becraft’s point is that biotechnology needs the same kind of proactive policy planning that AI is receiving.

The original biotech story is also useful because it is less politically charged than the Moderna COVID vaccine analogy. Ferriss asks whether using Moderna as the platform example creates problems because COVID vaccines are politicized. Becraft agrees that other analogies may be cleaner. He offers recombinant insulin: before biotechnology, insulin came from pig pancreases, which were harvested and processed. Early biotechnology took the insulin gene, inserted it into bacteria, and used bacteria to make the insulin protein. That became a platform for other recombinant proteins, including growth hormone and drugs such as Herceptin. This is the Genentech story and part of the Genzyme story.

The next stage, in Becraft’s view, is not just making proteins in tanks. It is getting therapeutic instructions to specific cells inside the body. He compares the iPhone to a delivery platform: Apple did not just make a device; it created a delivery system through which software, music, services, and other companies’ products could reach consumers. Each iPhone generation improved the form factor and capabilities, expanding what could be delivered.

The analogy serves one biotech claim: delivery systems change what can exist. For medicine, the analogous delivery solution is the ability to reach any cell and get the exact protein or instruction there. Near-term versions will still look like traditional drug development: design, manufacture, test, approve, and treat defined patient populations. Over 10 to 20 years, Becraft thinks the same infrastructure could enable hyper-personalized medicine.

He cites the “Baby KJ” story as an early example of personalized systemic CRISPR-based editing therapy for a fatal liver condition. The New York Times Opinion page shown on screen called it “the most important medical story of the decade”; other visuals described a baby diagnosed at Children’s Hospital of Philadelphia with CPS1 deficiency and stated, “In six months, they created a therapy just for KJ.” Becraft’s point is both hopeful and limiting: it was possible because the relevant correction needed to be made in the liver. That is meaningful for liver diseases, but kidney disease will not be solved in the liver, and neurodegeneration will not be solved in the liver. To generalize personalized medicine, delivery systems must reach other tissues.

Tim Ferriss’s initial attraction to Strand included more than the science. He describes Jake Becraft as a technical founder-builder for whom the company feels existential, not a hired-gun CEO. He also notes Becraft’s frustration with the conservatism and dogma he sees in Boston biotech. Becraft does not reject the characterization. He repeatedly returns to the contrast between earlier biotech founders and a modern industry he sees as too cautious.

His favorite historical texture is Genzyme’s “placenta mobile.” He says Genzyme founders drove around Boston collecting placentas from hospitals so they could purify a protein for a rare-disease drug. To Becraft, that is “the ultimate founder mode”: how do we stop this disease? The contrast he draws is with modern process language around target product profiles, FDA assumptions, proven mechanisms, and incremental moves. “We gotta just get our entrepreneurial pants back on and try to fix disease,” he says.

That frustration is linked to capital incentives. If the industry is built for pharma acquisition, founders will build what pharma wants. If the cost of failure is extremely high, investors will favor a drug that is 10 percent better over an unproven leap. If first-in-human trials cost $25 million and take 18 months just to begin, companies will ration shots on goal. The cumulative effect is not merely delay; in Becraft’s account, it changes what kinds of science get attempted.

Becraft’s preferred model accepts more hype and noise if that is the cost of taking transformative swings. He says San Francisco’s biotech culture is increasingly rivaling Boston because risk capital and openness to radical ideas are higher. That environment attracts hype, weak companies, and founders without substance, but he sees that as a low price for big swings. “One out of 10 transformations,” he says, is better than “seven out of 10 logical steps forward.”

Ferriss helps translate that into communication. The message should not be simplified because the audience is incapable. It should be structured so the audience can care quickly and then follow the complexity. The cancer patient story and scan provide stakes. The SpaceX analogy explains platform compounding. The policy ask gives policymakers something to do. The drug-versus-product distinction explains why clinical efficacy is not enough. The China competition adds urgency. The platform future gives the whole argument a reason beyond Strand’s current trial.

Becraft’s own takeaway from the messaging work is that scientists often default to explaining why something is complicated or broken. That can be accurate and still ineffective. The better sequence is: make someone care, state the urgency, show a plausible solution, and then invite them into the details.